Accès gratuit
Med Sci (Paris)
Volume 23, Numéro 3, Mars 2007
Page(s) 327 - 332
Section Forum
Publié en ligne 15 mars 2007
  1. Collins FS. Shattuck lecture: medical and societal consequences of the Human Genome Project. N Engl J Med 1999; 341 : 28–37.
  2. Khoury MJ, McCabe LL, McCabe ER. Population screening in the age of genomic medicine. N Engl J Med 2003; 348 : 50–8.
  3. Holtzman NA, Marteau TM. Will genetics revolutionize medicine ? N Engl J Med 2000; 343 : 141–4.
  4. Eden P, Ritz C, Rose C, et al. «Good Old »clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 2004; 40 : 1837–41.
  5. Moatti JP, Chanut C, Benech JM. Researcher-driven versus policy-driven economic appraisal of health technologies: the case of France. Soc Sci Med 1994; 38 : 1625–33.
  6. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000; 283 : 617–24.
  7. Tengs TO, Winer EP, Paddock S, et al. Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making 1998; 18 : 365–75.
  8. Kievit W, de Bruin JH, Adang EM, et al. Cost effectiveness of a new strategy to identify HNPCC patients. Gut 2005; 54 : 97–102.
  9. Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002; 359 : 572–7.
  10. Petricoin EF 3rd, Ornstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 2002; 94 : 1576–8.
  11. Davies RJ, Miller R, Coleman N. Colorectal cancer screening: prospects for molecular stool analysis. Nat Rev Cancer 2005; 5 : 199–209.
  12. Destro A, Bianchi P, Alloisio M, et al. K-ras and p16(INK4A)alterations in sputum of NSCLC patients and in heavy asymptomatic chronic smokers. Lung Cancer 2004; 44 : 23–32.
  13. Dulaimi E, Uzzo RG, Greenberg RE, et al. Detection of bladder cancer in urine by a tumor suppressor gene hypermethylation panel. Clin Cancer Res 2004; 10 : 1887–93.
  14. Crocitto LE, Korns D, Kretzner L, et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results. Urology 2004; 64 : 821–5.
  15. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 451–8.
  16. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17 : 3835–49.
  17. Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006; 59 : 557–63.
  18. Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286 : 531–7.
  19. Harris NL, Horning SJ. Burkitt’s lymphoma--the message from microarrays. N Engl J Med 2006; 354 : 2495–8.
  20. Olivier M, Hussain SP, Caron de Fromentel C, et al. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ 2004; 247–70.
  21. Brauch H, Weirich G, Hornauer MA, et al. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst 1999; 91 : 854–61.
  22. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet 2003; 362 : 1439–44.
  23. Baser ME, Kuramoto L, Woods R, et al. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. J Med Genet 2005; 42 : 540–6.
  24. Bertucci F, Houlgatte R, Granjeaud S, et al. Prognosis of breast cancer and gene expression profiling using DNA arrays. Ann NY Acad Sci 2002; 975 : 217–31.
  25. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 : 783–92.
  26. Meng S, Tripathy D, Shete S, et al. HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci USA 2004; 101 : 9393–8.
  27. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20 : 1800–8.
  28. Dervieux T, Meshkin B, Neri B. Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. Mutat Res 2005; 573 : 180–94.
  29. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91 : 2001–8.
  30. Mathijssen RH, de Jong FA, van Schaik RH, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004; 96 : 1585–92.
  31. Bernard-Marty C, Cardoso F, Sotiriou C, Piccart MJ. Vers une individualisation du traitement systémique du cancer du sein. Bull Cancer 2006; 93 : 791–7.
  32. Warnock M. Some moral problems in medicine. Health Econ 1994; 3 : 297–300.
  33. Haddow J, Palomaki G. ACCE: a modelprocess for evaluating data on emerging genetic tests. In: Khoury M, Little J, Burke W, eds. Human genome epidemiology. New York : Oxford University Press ; 2004 : 217–233.
  34. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. Replication validity of genetic association studies. Nat Genet 2001; 306–9.
  35. Simon R. Development and validation of therapeutically relevant multi-gene biomarker classifiers. J Natl Cancer Inst 2005; 97 : 866–7.
  36. Camargo MC, Mera R, Correa P, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms and gastric cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15 : 1674–87.
  37. Simon R, Radmacher MD, Dobbin K, McShane LM. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95 : 14–8.
  38. Harris R. Effectiveness: the next question for breast cancer screening. J Natl Cancer Inst 2005; 97 : 1021–3.
  39. Lerman C, Hughes C, Lemon SJ, et al. What you don’t know can hurt you: adverse psychologic effects in members of BRCA1-linked and BRCA2-linked families who decline genetic testing. J Clin Oncol 1998; 16 : 1650–4.
  40. Julian-Reynier C, Eisinger F, Chabal F, et al. Disclosure to the family of breast/ovarian cancer genetic test results: Patient’s willingness and associated factors. Am J Med Genet 2000; 94 : 13–8.
  41. Deftos LJ. The evolving duty to disclose the presence of genetic disease to relatives. Acad Med 1998; 73 : 962–8.
  42. Keogh LA, Southey MC, Maskiell J, et al. Uptake of offer to receive genetic information about BRCA1 and BRCA2 mutations in an Australian population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13 : 2258–63.
  43. Porteous M, Dunckley M, Appleton S, et al. Is it acceptable to approach colorectal cancer patients at diagnosis to discuss genetic testing ? A pilot study. Br J Cancer 2003; 89 : 1400–2.
  44. Keller M, Jost R, Kadmon M, et al. Acceptance of and attitude toward genetic testing for hereditary nonpolyposis colorectal cancer: a comparison of participants and nonparticipants in genetic counseling. Dis Colon Rectum 2004; 47 : 153–62.
  45. Braithwaite D, Emery J, Walter F, et al. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2004; 96 : 122–33.
  46. Hoy M, Orsi F, Eisinger F, Moatti J. The Impact of genetic testing on Healthcare Insurance. The Geneva Papers on Risk and Insurance 2003; 203–21.
  47. Smith C. Genomics: getting down to details. Nature 2005; 435 : 991–4.
  48. Schrag D, Kuntz KM, Garber JE, Weeks JC. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997; 336 : 1465–71.
  49. Heiskanen I, Luostarinen T, Jarvinen HJ. Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 2000; 35 : 1284–7.
  50. Jarvinen HJ, Aarnio M, Mustonen H, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118 : 829–34.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.